Toward stratification of patients with pancreatic cancer: Past lessons from traditional approaches and future applications with physical biomarkers.

•PDAC has heterogeneous inter-patient and intra-tumoral physical features.•The heterogeneous physical properties may explain the variable treatment response.•Promising drugs have not been successful partly due to lack of selection markers.•Physical biomarkers of PDAC may be used to stratify patients in clinical trials.